Development and evaluation of Deferasirox loaded nanoparticles for the treatment of Breast cancer: evaluation in-vitro and cell line study

Abstract

Introduction: The aim of the present study was to study the potential efficacy of antitumor activity of nanoparticles loaded with Deferasirox In the current research work, nanoparticle loaded with Deferasirox were developed and evaluated to study its efficacy using breast cancer cell line. Nanoparticles of Deferasirox were prepared by solvent evaporation method using EthocelTM as a polymer and Kolliphor® P 188 as a surfactant. 23 factorial design used with concentration of polymer, concentration of surfactant and rpm as independent variables and percentage of entrapment efficiency and percentage of drug release as dependent variables. All formulations were prepared and evaluated for particle size, spectral studies, thermal studies, drug entrapment efficiency and in-vitro drug dissolution studies. In-vitro cell viability study on breast cancer cell line (MCF-7) was performed by MTT assay Developed nanoparticles possess the particle size 428.3 nm and PDI 0.626. Optimized formulation showed 82.62±1.04 maximum drug release after 6 h in a controlled manner and entrapment efficiency 72.64±0.24. The FTIR spectral studies and DSC thermogram indicated that there was no interaction between the drug and polymers used. Thus, Deferasirox nanoparticle formulation showed the anti-tumoral activity against human breast cancer cell line (MCF7) as per outcome of cell line study Nanoparticles of Deferasirox were stable and could be promising drug delivery for cancerous cells.